Proposed MRI Safety Monitoring of Patients with Multiple Sclerosis Treated with Natalizumab

Česká verzia

Authors: M. Vaněčková ¹; Z. Seidl ¹; Pracovní Radiologická Skupina ^*
Authors place of work: Oddělení MR, Radiodiagnostická klinika 1. LF UK a VFN v Praze ¹
Published in the journal: Cesk Slov Neurol N 2016; 79/112(6): 663-669
Category: Review Article

* Pracovní radiologická skupina: F. Čáp², E. Čecháková³, J. Havelka⁴, M. Keřkovský⁵, J. Kubále⁶, J. Lisý⁷, M. Mrklovský^8,9, M. Pažourková¹⁰, P. Ryška¹¹, Z. Ryznarová¹², R. Tupý¹³, J. Tesař¹⁴ ²Radiodiagnostická klinika 3. LF UK a FN Královské Vinohrady, Praha, ³Radiologická klinika LF OU a FN Olomouc, ⁴Ústav radiodiagnostický, LF OU a FN Ostrava, ⁵Radiologická klinika LF MU a FN Brno, ⁶Radiologické oddělení, Nemocnice České Budějovice, a.s., ⁷Klinika zobrazovacích metod 2. LF UK a FN v Motole, Praha, ⁸Onkologické a radiologické centrum Multiscan Pardubice, ⁹Radiodiagnostické oddělení, Nemocnice Pardubického kraje, a.s., ¹⁰Klinika zobrazovacích metod LF MU a FN u Sv. Anny v Brně, ¹¹Radiologická klinika LF UK a FN Hradec Králové, ¹²Pracoviště magnetické rezonance a fokusovaného ultrazvuku, Thomayerova nemocnice, Praha, ¹³Klinika zobrazovacích metod, LF UK a FN Plzeň, ¹⁴Oddělení zobrazovacích metod, Krajská nemocnice T. Bati, a.s., Zlín

Summary

An expert panel of radiologists specialized in MRI monitoring of patients with multiple sclerosis proposes a safety protocol for monitoring of patients with increased risk of progressive multifocal leukoencephalopathy (PML). Patients administered natalizumab for longer than two years in whom anti JC virus antibodies have been detected have a higher risk of developing PML. PML is a rare opportunistic infection that occurs in immunocompromised patients. Over the last decade, PML was reported to be associated with administration of monoclonal antibodies. The disease has high lethality and severe clinical course. There is currently no effective treatment. Early diagnosis, followed by treatment interruption and natalizumab elimination, is the only factor that influences patient prognosis. Regular monitoring with magnetic resonance imaging enables detection of the subclinical stage of the disease, thereby significantly improving patient prognosis. This paper proposes essential MRI safety monitoring (protocol testing, monitoring frequency) and emphasises close cooperation between radiologists and neurologists. It also shows the characteristic MRI features of the disease and discusses published literature summarising early stage findings. The paper seeks to highlight the imaging characteristics that help to distinguish PML from an MS relapse, i.e. the most common differential diagnostic problem.

Key words:
progressive multifocal leukoencephalopathy – magnetic resonance imaging – safety monitoring – natalizumab

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Zdroje

1. Keen DL, Legare C, Taylor E, et al. Monoclonal Antibodies and Progressive Multifocal Leukoencephalopathy. Can J Neurol Sci 2011;38(4):565– 71.

2. Sahraian MA, Radue EW, Eshaghi A, et al. Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis. Eur J Neurol 2012;19(8):1060– 9.

3. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders by JC virus: clinical features and pathogenesis. Lancet Neurol 2010;9(4):425– 37. doi: 10.1016/ S1474-4422(10)70040-5.

4. Weissert R. Progressive multifocal leukoencephalopathy. J Neuroimmunol 2011;231(1– 2):73– 7. doi: 10.1016/ j.jneuroim.2010.09.021.

5. Honce JM, Nagae L, Nyberg E. Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities. Mult Scler Int 2015,2015:809252. doi: 10.1155/ 2015/ 809252.

6. Rosenkrantz T, Novas M, Terborg C. PML in a patient with lymphocytopenia treated with dimethyl fumarate. N Engl J Med 2015; 372(15):1476– 8. doi: 10.1056/ NEJMc1415408.

7. Rozsypal H, Jilich D, Hubacek P, et al. Úskalí diagnostiky progresivní multifokální leukoencefalopatie u pacientů infikovaných lidským virem imunodeficience – kazuistiky. Cesk Slov Neurol N 2013;76/ 109(4):501– 7.

8. Horáková D, Havrdová E. Protilátky proti JC viru a stratifikace rizika progresivní multifokální leukoencefalopatie u pacientů s roztroušenou sklerózou. Doporučení k použití nového testu STRATIFY JCVTM. Neurol Praxi 2011;12(5):364– 5.

9. Egli A, Infanti L, Dumoulin A, et al. Prevalence of Polyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors. J Infect Dis 2009;199(6):837– 46.

10. Trampe AK, Hemmelmann C, Stroet A, et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology 2012;78(22):1736– 42. doi: 10.1212/ WNL.0b013e3182583022.

11. Dong-Si T, Richman S, Wattjes MP, et al. Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Clin Transl Neurol 2014;1(10):755– 64. doi: 10.1002/ acn3.114.

12. Dong-Si T, Gheuens S, Gangadharan A, et al. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. J Neurovirol 2015;21(6):637– 44. doi: 10.1007/ s13365-015-0316-4.

13. Berger JR. The clinical features of PML. Cleve ClinJ Med2011;78(Suppl 2):S8– 12.

14. Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 2013;80(15):1430– 8. doi: 10.1212/ WNL.0b013e31828c2fa1.

15. Chalkley JJ, Berger JR. Progressive multifocal leukoencephalopathy in multiple sclerosis. Curr Neurol Neurosci Rep 2013;13(12):408. doi: 10.1007/ s11910-013-0408-6.

16. Wattjes MP, Richert ND, Killestein J, et al. The chameleon of neuroinflammation magnetic resonance paging characteristics of natalizumab – associated progressive multifocal leukoencephalopathy. Mult Scler 2013;19(14):1826– 40. doi: 10.1177/ 1352458513510224.

17. Clifford DB, DeLucca A, Simpson DM, et al. Natalizumab-associated progresive multifocal leukoencefalopathy in patiens with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010;9(4):438– 46. doi: 10.1016/ S1474-4422(10)70028-4.

18. Ayzenberg I, Lukas C, Trampe N, et al. Value of MRI as a surrogate marker for PML in natalizumab long-term therapy. J Neurol 2012;259(8):1732– 3.

19. Blair NF, Brew BJ, Halpern JP. Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance. Neurology 2012;78(7):507– 8. doi: 10.1212/ WNL.0b013e318246d6d8.

20. Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014;76(6):802– 12. doi: 10.1002/ ana.24286.

21. Štětkářová I, Medová E, Bučilová V, et al. Progresivní multifokální leukoencefalopatie u nemocné s roztroušenou sklerózou léčenou natalizumabem. Ces Radiol 2013;67(1):35– 8.

22. Wattjes MP, Vennegoor A, Steenwijk MD, et al. MRI pattern in asymptomatic natalizumab-associated PML. J Neurol Neurosurg Psychiatry 2015;86(7):793– 8. doi: 10.1136/ jnnp-2014-308630.

23. Hodel J, Outteryck O, Dubron C, et al. Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab: diagnostic precision with MR imaging. Radiology 2016;278(3):863– 72. doi: 10.1148/ radiol.2015150673.

24. McGulgan C, Craner M, Guadagno J, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry 2016;87(2):117– 25. doi: 10.1136/ jnnp-2015-311100.

25. Blair NF, Brew BJ, Halpern JP. Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance. Neurology 2012;78(7):507– 8. doi: 10.1212/ WNL.0b013e318246d6d8.

26. Taieb G, Renard D, Thouvenont E, et al. Transient punctate enhancing lesions preciding natalizumab-associated progressive multifocal leukoencephalopathy. J Neurol Sci 2014;346(1– 2):364– 5. doi: 10.1016/ j.jns.2014.09.007.

27. Richert N, Bloomgren G, Cadavid D. Imaging findings for PML in natalizumab-treated MS patients. Mult Scler 2012;18(Suppl 4):27– 8.

28. Bergui M, Bradac GB, Oguz KK, et al. Progressive multifocal leukoencephalopathy: diffusion-weighted paging and pathological correlations. Neuroradiology 2004;46(1):22– 5.

29. Wattjes MP, Steenwijk MD, Stangel M. MRI in the diagnosis and monitoring of multiple sclerosis: an update. Clin Neuroradiol 2015; 25(Suppl 2):157– 65. doi: 10.1007/ s00062-015-0430-y.

30. Yousry TA, Pelletier D, Cadavid D, et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2012;72(5):779– 87. doi: 10.1002/ ana.23676.

31. Wattjes MP, Wijburg MT, Vennegoor A, et al. MRI characteristics of early PML-IRIS after natalizumab treatment in patiens with MR. J Neurol Neurosurg Psychiatry 2015;78(8):879– 84. doi: 10.1136/ jnnp-2015-311411.

32. Wattjes MP, Wijburg MT, Vennegoor A, et al. Diag-nostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patiens. Mult Scler 2016;22(9):1174– 83. doi: 10.1177/ 1352458515615225.

33. Wattjes MP, Vennegoor A, Mostert J, et al. Diag-nosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place? J Neurol 2014;261(6):1139– 43. doi: 10.1007/ s00415-014-7336-5.

34. Killestein J, Vennegoor A, van Golde AE, et al. PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation. Case Rep Neurol Med 2014;2014:307872. doi: 10.1155/ 2014/ 307872.

35. Vaněčková M, Seidl Z, Krásenský J, et al. Naše zkušenosti s MR monitorací pacientů s roztroušenou sklerózou v klinické praxi Čes Slov Neurol N 2010;73/ 106(6):716– 20.